Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer

Annals of Medicine

Volumn 34, Issue 7-8, 2002, Pages 554-564

  McGriff, Nayahmka J ^a   Csako, Gyorgy ^a   Gourgiotis, Loukas ^b   Guthrie, Lori C ^b   Pucino, Frank ^a   Sarlis, Nicholas J ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Levothyroxine; Meta analysis; Outcome; Progression; Suppression; Survival; Thyroid cancer; Thyroid hormone

Indexed keywords

LEVOTHYROXINE; THYROID EXTRACT; THYROID HORMONE; THYRONINE; THYROTROPIN;

ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; EPIDEMIOLOGY; HORMONE INHIBITION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RATING SCALE; RISK ASSESSMENT; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROTROPIN BLOOD LEVEL; THYROTROPIN RELEASE; TREATMENT OUTCOME;

EID: 0036957966     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/078538902321117760     Document Type: Article

References (74)

1. Anonymous. Surveillance, epidemiology, and end results (SEER) program public-use data (1973-1998). National Cancer Institute, DCCPS, Surveillance research program, cancer Statistics Branch (April 2001).
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U S, 1985-1995 Cancer 1998; 83: 2638-48.
3. Kebebew E, Clark OH. Differentiated thyroid cancer: "complete" rational approach. World J Surg 2000; 24: 942-51.
4. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86: 1447-63.
5. Clark OH. TSH suppression in the management of thyroid nodules and thyroid cancer. World J Surg 1981; 5: 39-47.
6. Sheils OM, Sweeney EC. TSH receptor status of thyroid neoplasms-TaqMan RT-PCR analysis of archival material. J Pathol 1999; 188: 87-92.
7. Tanaka K, Inoue H, Miki H, Masuda E, Kitaichi M, Komaki K, et al. Relationship between prognostic score and thyrotropin receptor (TSH-R) in papillary thyroid carcinoma: immunohistochemical detection of TSH-R. Br J Cancer 1997; 75: 594-9.
8. Cai WY, Lukes YG, Burch HB, Djuh YY, Carr F, Wartofsky L, et al. Analysis of human TSH receptor gene and RNA transcripts in patients with thyroid disorders. Autoimmunity 1992; 13: 43-50.
9. Goretzki PE, Koob R, Koller T, Simon R, Branscheid D, Clark OH, et al. The effect of thyrotropin and cAMP on DNA synthesis and cell growth of human thyrocytes in monolayer culture. Surgery 1986; 100: 1053-61.
10. Cetani F, Tonacchera M, Pinchera A, Barsacchi R, Basolo F, Miccoli P, et al. Genetic analysis of the TSH receptor gene in differentiated human thyroid carcinomas. J Endocrinol Invest 1999; 22: 273-8.
11. Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev 2001; 22: 631-56.
12. Gartner R. Thyroid growth in vitro. Exp Clin Endocrinol 1992; 100: 32-5.
13. Dunhill (Sir) TP. The surgery of the thyroid gland: the Lettsomian lectures. Trans Med Soc Lond 1937; 60: 234-82.
14. Crile G, Jr. Endocrine dependency of papillary carcinomas of the thyroid. JAMA 1966; 195: 721-4.
15. Crile G, Jr. Changing end results in patients with papillary carcinoma of the thyroid. Surg Gynecol Obstet 1971; 132: 460-8.
16. Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT, Page CP. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore) 1977; 56: 171-96.
17. Young RL, Mazzaferri EL, Rahe AJ, Dorfman SG. Pure follicular thyroid carcinoma: impact of therapy in 214 patients. J Nucl Med 1980; 21: 733-7.
18. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 1981; 70: 511-8.
19. Wanebo HJ, Andrews W, Kaiser DL. Thyroid cancer: some basic considerations. Am J Surg 1981; 142: 474-9.
20. Cady B, Cohn K, Rossi RL, Sedgwick CE, Meissner WA, Werber J, et al. The effect of thyroid hormone administration upon survival in patients with differentiated thyroid carcinoma. Surgery 1983; 94: 978-83.
21. Girelli ME, Busnardo B, Amerio R, Scotton G, Casara D, Betterle C, et al. Serum thyroglobulin levels in patients with well-differentiated thyroid cancer during suppression therapy: study on 429 patients. Eur J Nucl Med 1985; 10: 252-4.
22. McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 1986; 61: 978-96.
23. Mazzaferri EL. Papillary thyroid carcinoma: factors influencing prognosis and current therapy. Semin Oncol 1987; 14: 315-32.
24. Rossi RL, Cady B, Silverman ML, Wool MS, ReMine SG, Hodge MB, et al. Surgically incurable well-differentiated thyroid carcinoma. Prognostic factors and results of therapy. Arch Surg 1988; 123: 569-74.
25. Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz, MK Sutcliffe SB. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988; 14: 1063-75.
26. Cunningham MP, Duda RB, Recant W, Chmiel JS, Sylvester JA, Fremgen A. Survival discriminants for differentiated thyroid cancer. Am J Surg 1990; 160: 344-7.
27. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-28.
28. Staunton MD. Thyroid cancer: a multivariate analysis on influence of treatment on long-term survival. Eur J Surg Oncol 1994; 20: 613-21.
29. Jaffiol C, Daures JP, Nsakala N, Guerenova J, Baldet L, Pujol P, et al. Long term follow up of medical treatment of differentiated thyroid cancer. (In French) Ann Endocrinol (Paris) 1995; 56: 119-26.
30. Sanders LE, Rossi RL. Occult well differentiated thyroid carcinoma presenting as cervical node disease. World J Surg 1995; 19: 642-7.
31. Herrera MF, Lopez-Graniel CM, Saldana J, Gamboa-Dominguez A, Richaud-Patin Y, Vargas-Vorackova F, et al. Papillary thyroid carcinoma in Mexican patients: clinical aspects and prognostic factors. World J Surg 1996; 20: 94-9.
32. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996; 81: 4318-23.
33. Esik O, Tusnady G, Daubner K, Nemeth G, Fuzy M, Szentirmay Z. Survival chance in papillary thyroid cancer in Hungary: individual survival probability estimation using the Markov method. Radiother Oncol 1997; 44: 203-12.
34. Martins RG, Caplan RH, Lambert PJ, Rooney B, Kisken WA. Management of thyroid cancer of follicular cell origin: Gundersen/Lutheran Medical Center, 1969-1995. J Am Coll Surg 1997; 185: 388-97.
35. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, et al. Thyroid Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998; 8: 737-44.
36. Fujimoto Y, Sugitani I. Postoperative prognosis of intrathyroidal papillary thyroid carcinoma: long-term (35-45 year) follow-up study. Endocr J 1998; 45: 475-84.
37. Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med 1998; 129: 622-7.
38. Böhm J, Kosma VM, Eskelinen M, Hollmen S, Niskanen M, Tulla H, et al. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma. Eur J Endocrinol 1999; 141: 460-7.
39. Kamel N, Gullu S, Dagci Ilgin S, Corapcioglu D, Tonyukuk Cesur V, Uysal AR, et al. Degree of thyrotropin suppression in differentiated thyroid cancer without recurrence or metastases. Thyroid 1999; 9: 1245-8.
40. Wang PW, Wang ST, Liu RT, Chien WY, Tung SC, Lu YC, et al. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999; 84: 4549-53.
41. Jarzab B, Handkiewicz Junak D, Wloch J, Kalemba B, Roskosz J, Kukulska A, et al. Multivariate analysis of prognostic factors for differentiated thyroid carcinoma in children. Eur J Nucl Med 2000; 27: 833-41.
42. Csako G, Byrd D, Wesley RA, Sarlis NJ, Skarulis MC, Nieman LK, et al. Assessing the effects of thyroid suppression on benign solitary thyroid nodules. A model for using quantitative research synthesis. Medicine (Baltimore) 2000; 79: 9-26.
43. Mosteller F, Colditz GA. Understanding research synthesis (meta-analysis). Annu Rev Public Health 1996; 17: 1-23.
44. Mulrow C, Cook D. Systematic Reviews: Synthesis of Best Evidence for Health Care Decisions. Philadelphia: American College of Physicians; 1998.
45. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyrotropin (TSH) assays. Clin Chem 1996; 42: 140-5.
46. Dong BJ. Thyroid disorders. In: Young LY, Koda-Kimble MA, eds. Applied Therapeutics: The Clinical Use of Drugs. 6th ed. Vancouver; 1996: 47-131.
47. Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med 1987; 316: 764-70.
48. Hill AB. The environment and disease: association or causation? Proc Royal Soc Med 1965; 58: 295-300.
49. Anonymous. SAS/STAT User's Guide: version 6. 4th edn. Cary; SAS Institute, 1990.
50. Ross DS. Long-term management of differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990; 19: 719-39.
51. Cady B. Papillary carcinoma of the thyroid. Semin Surg Oncol 1991; 7: 81-6.
52. Thomas CG, Jr. Role of thyroid stimulating hormone suppression in the management of thyroid cancer. Semin Surg Oncol 1991; 7: 115-9.
53. Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid disease. Ann Intern Med 1993; 119: 492-502.
54. McClellan DR, Francis GL. Thyroid cancer in children, pregnant women, and patients with Graves' disease. Endocrinol Metab Clin North Am 1996; 25: 27-48.
55. Singer PA, Cooper DS, Daniels GH, Ladenson PW, Greenspan FS, LevyEG, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. Arch Intern Med 1996; 156: 2165-72.
56. Fuchshuber P, Loree TR, DeLacure MD, Hicks WL, Jr. Differentiated thyroid carcinoma: risk group assignment and management controversies. Oncology 1998 12: 99-106.
57. Paloyan E, Walker RP, Lawrence AM. Guidelines for the use of radioiodine, thyroid hormone, and treatment of metastatic disease in patients with differentiated thyroid cancer. Surg Oncol Clin N Am 1998; 7: 665-80.
58. Mazzaferri EL. 1999 NCCN Thyroid Carcinoma Practice Guidelines. National Cancer Center Network Proceedings 1999; 13: 391-442. (also available on Internet site: http:// www.nccn.org; accessibility verified on July 3, 2002).
59. Sherman SI. Adjuvant therapy and long-term management of differentiated thyroid carcinoma. Semin Surg Oncol 1999; 16: 30-3.
60. St. Louis JD, Leight GS, Tyler DS. Follicular neoplasms: the role for observation, fine needle aspiration biopsy, thyroid suppression, and surgery. Semin Surg Oncol 1999; 16: 5-11.
61. Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract 2000; 6: 469-76.
62. Cobin RH, Gharib H. AACE/AAES. Medical/Surgical guidelines for clinical practice: management of thyroid carcinoma. Endocr Prac 2001; 7: 203-20.
63. Kuriakose MA, Hicks WL, Jr., Loree TR, Yee H. Risk group-based management of differentiated thyroid carcinoma. J R Coll Surg Edinb 2001; 46: 216-23.
64. van Tol KM, de Vries EG, Dullaart RP, Links TP. Differentiated thyroid carcinoma in the elderly. Crit Rev Oncol Hematol 2001; 38: 79-91.
65. British Thyroid Association. Guidelines for the management of thyroid cancer. London: Royal College of Physicians; 2002 (also available on Internet site: http://www.british-thyroid-association.org/guidelines.htm; accessibility verified on July 3, 2002).
66. Vassart G, Dumont JE. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev 1992; 13: 596-611.
67. Hoelting T, Goretzki PE, Duh QY. Follicular thyroid cancer cells: a model of metastatic tumor in vitro. Oncol Rep 2001; 8: 3-8.
68. Dralle H, Bocker W, Dohler KD, Schröder S, Haindl H, Geerlings H, et al. Growth and function of thirty-four human benign and malignant thyroid xenografts in untreated nude mice. Cancer Res 1985; 45: 1239-45.
69. Cho JY, Sagartz JE, Capen CC, Mazzaferri EL, Jhiang SM. Early cellular abnormalities induced by RET/PTC1 oncogene in thyroid-targeted transgenic mice. Oncogene 1999; 18: 3659-65.
70. Namba H, Yamashita S, Usa T, Kimura H, Yokoyama N, Izumi M, et al. Overexpression of the intact thyrotropin receptor in a human thyroid carcinoma cell line. Endocrinology 1993; 132: 839-45.
71. Friedland DJ. Evidence-based Medicine: A Framework for Clinical Practice. Stamford: Appleton & Lange; 1998.
72. Sackett DL, Richardson WS, Rosenberg W, Haynes RB. Evidence-based Medicine: How to Practice and Teach EBM. 2nd edn. New York: Churchill Livingstone; 2000.
73. Jonklaas J, Sarlis N, Litofsky D, Cooper D, Ain K, Bigos S, et al. Both near total/total thyroidecromy (NTT) and thyroid hormone suppression therapy (THST) improve survival of patients with papillary thyroid carcinoma. Proc 73rd Ann Mtg Am Thyroid Assoc 2001; Washington, DC.
74. Williams JB. Adverse effects of thyroid hormones. Drugs Aging 1997; 11: 460-9.